Índice de Identificação do Risco de Disfunção Ventricular Decorrente do Tratamento Antineoplásico: Elaboração e Validação de Conteúdo
DOI:
https://doi.org/10.32635/2176-9745.RBC.2026v72n1.5420Palavras-chave:
Agentes Antineoplásicos/efeitos adversos, Radioterapia/efeitos adversos, Cardiotoxicidade/prevenção & controle, Disfunção Ventricular/prevenção & controle, Medição de RiscoResumo
Introdução: O risco de cardiotoxicidade associada aos tratamentos antineoplásicos, especialmente a disfunção ventricular, evidencia a necessidade de instrumentos eficazes e multiprofissionais para prevenção, detecção e manejo dessas complicações. Objetivo: Elaborar e validar o conteúdo do Índice de Risco de Disfunção Ventricular Decorrente do Tratamento Antineoplásico. Método: Estudo metodológico de elaboração e validação de conteúdo de um índice, dividido em duas fases. Na primeira fase, realizou-se uma revisão da literatura, a partir da qual o índice foi desenvolvido. Na segunda fase, a versão inicial foi elaborada pelos autores e submetida à apreciação de 33 especialistas. Seis reuniões de consenso foram realizadas entre agosto e outubro de 2022. Resultados: Na etapa de revisão, foram identificados os fatores de risco para disfunção ventricular relacionados ao tratamento sistêmico antineoplásico atual, à radioterapia atual, ao tratamento antineoplásico prévio, ao paciente e ao estilo de vida. A versão atual do instrumento serve como guia para anamnese/ triagem de pessoas com câncer, até que sua capacidade preditiva seja confirmada. Conclusão: Após o processo de validação, a versão final do índice passou a contar com um texto instrucional para seu preenchimento, composto por 21 itens agrupados conforme a natureza dos fatores de risco e as respectivas alternativas de resposta, sem pesos estatísticos dos itens claramente definidos.
Downloads
Referências
Santos MO, Lima FCS, Martins LFL, et al. Estimativa de incidência de câncer no Brasil. Rev Bras Cancerol. 2023;69(1):e-213700. doi: https://doi.org/10.32635/2176-9745.rbc.2023v69n1.3700 DOI: https://doi.org/10.32635/2176-9745.RBC.2023v69n1.3700
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi: https://doi.org/10.3322/caac.21763 DOI: https://doi.org/10.3322/caac.21763
Zanini LAG, Reis RJ, Laporte GA, et al. Análise do manejo cirúrgico de pacientes com câncer cervical recidivado após radioterapia e quimioterapia. Rev Col Bras Cir. 2020;47(1):e20202443. doi: https://doi.org/10.1590/0100-6991e-20202443 DOI: https://doi.org/10.1590/0100-6991e-20202443
Ceglio WQGW, Rebeis MM, Santana MF, et al. Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital. An Bras Dermatol. 2022;97(1):14-21. doi: https://doi.org/10.1016/j.abd.2021.05.007 DOI: https://doi.org/10.1016/j.abd.2021.05.007
Corrêa FE, Alves MK. Chemotherapy: side effects and influence on the nutritional status of cancer patients. Uniciências. 2018;22(2):100-5. doi: https://doi.org/10.17921/1415-5141.2018v22n2p100-105 DOI: https://doi.org/10.17921/1415-5141.2018v22n2p100-105
Melo MDT, Paiva MG, Santos MVC, et al. Posicionamento brasileiro sobre o uso da multimodalidade de imagens na Cardio-Oncologia - 2021. Arq Bras Cardiol. 2021;117(4):845-909. doi: https://doi.org/10.36660/abc.20200266 DOI: https://doi.org/10.36660/abc.20200266
Hajjar LA, Costa IBSS, Lopes MACQ, et al. Diretriz Brasileira de Cardio-oncologia-2020. Arq Bras Cardiol. 2020;115(5):1006-43. doi: https://doi.org/10.36660/abc.20201006 DOI: https://doi.org/10.36660/abc.20201006
Armenian SH, Lacchetti C, Barac A, et al. Prevention and Monitoring Of Cardiac Dysfunction In Survivors Of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893-911. doi: https://doi.org/10.1200/JCO.2016.70.5400 DOI: https://doi.org/10.1200/JCO.2016.70.5400
Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171-90. doi: https://doi.org/10.1016/j.annonc.2019.10.023 DOI: https://doi.org/10.1016/j.annonc.2019.10.023
Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457-65. doi: https://doi.org/10.1200/JCO.2011.34.7625 DOI: https://doi.org/10.1200/JCO.2011.34.7625
Hurria A, Mohile S, Gajra A, et al. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol. 2016;34(20):2366-71. doi: https://doi.org/10.1200/JCO.2015.65.4327 DOI: https://doi.org/10.1200/JCO.2015.65.4327
Pontes LB, Chinaglia L, Karnakis T, et al. Chemotherapy in the elderly: translation of Hurria’s toxicity score to portuguese. Geriatr Gerontol Aging. 2017;11(2):76-9. doi: https://doi.org/10.5327/Z2447-211520171700040 DOI: https://doi.org/10.5327/Z2447-211520171700040
Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377-86. doi: https://doi.org/10.1002/cncr.26646 DOI: https://doi.org/10.1002/cncr.26646
Kim DY, Park MS, Youn JC, et al. Development and validation of a risk score model for predicting the cardiovascular outcomes after breast cancer therapy: the CHEMO-RADIAT score. J Am Heart Assoc.2021;10(16):e021931. doi: https://doi.org/10.1161/JAHA.121.021931 DOI: https://doi.org/10.1161/JAHA.121.021931
Prinsen CA, Vohra S, Rose MR, et al. How to select outcome measurement instruments for outcomes included in a “Core Outcome Set” – a practical guideline. Trials. 2016;17(1):449. doi: https://doi.org/10.1186/s13063-016-1555-2 DOI: https://doi.org/10.1186/s13063-016-1555-2
Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4(5):1-7. doi: https://doi.org/10.1186/s41073-019-0064-8 DOI: https://doi.org/10.1186/s41073-019-0064-8
Ribeiro ML, Jorge AJL, Nacif MS, et al. Early detection and monitoring of cancer chemotherapy-related left ventricular dysfunction by imaging methods. Arq Bras Cardiol. 2019;112(3):309-16. doi: https://doi.org/10.5935/abc.20190022 DOI: https://doi.org/10.5935/abc.20190022
Sadler GR, Lee HC, Lim RS, et al. Recruitment of hard-to-reach population subgroups via adaptations of the snowball sampling strategy. Nurs Health Sci. 2010;12(3):369-74. doi: https://doi.org/10.1111/j.1442-2018.2010.00541.x DOI: https://doi.org/10.1111/j.1442-2018.2010.00541.x
Polit DE, Beck CT. Fundamentos de pesquisa em enfermagem: avaliação de evidências para a prática da enfermagem. 9. ed. Porto Alegre: Artmed; 2019.
Terwee CB, Prinsen CAC, Chiarotto A, et al. COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study. Qual Life Res. 2018;27(5):1159-70. doi: https://doi.org/10.1007/s11136-018-1829-0 DOI: https://doi.org/10.1007/s11136-018-1829-0
Mokkink LB, Vet HCW, Prinsen CAC, et al. COSMIN Risk of Bias checklist for systematic reviews of Patient-Reported Outcome Measures. Qual Life Res. 2018;27(5):1171-9. doi: https://doi.org/10.1007/s11136-017-1765-4 DOI: https://doi.org/10.1007/s11136-017-1765-4
Conselho Nacional de Saúde (BR). Resolução n° 466, de 12 de dezembro de 2012. Aprova as diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos. Diário Oficial da União, Brasília, DF. 2013 jun 13; Seção I:59.
Alexandre J, Cautela J, Ederhy S, et al. Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European cardio-oncology guidelines. J Am Heart Assoc. 2020;9(18):e018403. doi: https://doi.org/10.1161/JAHA.120.018403 DOI: https://doi.org/10.1161/JAHA.120.018403
Adão R, Keulenaer G, Leite-Moreira A, et al. Cardiotoxicidade associada à terapêutica oncológica: mecanismos fisiopatológicos e estratégias de prevenção. Rev Port Cardiol. 2013;32(5):395-409. doi: https://doi.org/10.1016/j.repc.2012.11.002 DOI: https://doi.org/10.1016/j.repc.2012.11.002
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity. Eur Heart J. 2016;37(36):2768- 801. doi: https://doi.org/10.1093/eurheartj/ehw211 DOI: https://doi.org/10.1093/eurheartj/ehw211
Copeland-Halperin RS, Liu JE, Yu AF. Cardiotoxicity of HER2-targeted therapies. Curr Opin Cardiol. 2019;34(4):451-8. doi: https://doi.org/10.1097/HCO.0000000000000637 DOI: https://doi.org/10.1097/HCO.0000000000000637
Dempsey N, Rosenthal A, Dabas N, et al. Trastuzumabinduced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat. 2021;188(1):21-36. doi: https://doi.org/10.1007/s10549-021-06280-x DOI: https://doi.org/10.1007/s10549-021-06280-x
Nicolazzi MA, Carnicelli A, Fuorlo M, et al. Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer. Eur Rev Med Pharmacol Sci. 2018;22(7):2175-85. doi: https://doi.org/10.26355/eurrev_201804_14752
Iqubal A, Iqubal MK, Sharma S, et al. Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: old drug with a new vision. Life Sci. 2019;218:112-31. doi: https://doi.org/10.1016/j. lfs.2018.12.018 DOI: https://doi.org/10.1016/j.lfs.2018.12.018
Pinto CM, Silva CMPDC, Pinto GH, et al. Quimioterapia e cardiotoxicidade. Rev Soc Cardiol Estado São Paulo. 2017;27(4):266-73. doi: https://doi.org/10.29381/0103-8559/20172704266-73 DOI: https://doi.org/10.29381/0103-8559/20172704266-73
Choksey A, Timm KN. Cancer therapy-induced cardiotoxicity - a metabolic perspective on pathogenesis, diagnosis and therapy. Int J Mol Sci. 2021;23(1):441. doi: https://doi.org/10.3390/ijms23010441 DOI: https://doi.org/10.3390/ijms23010441
Jain D, Aronow W. Cardiotoxicity of cancer chemotherapy in clinical practice. Hosp Pract. 2018;47(1):6-15. doi: https://doi.org/10.1080/21548331.2018.1530831 DOI: https://doi.org/10.1080/21548331.2018.1530831
Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol. 2018;2(13):1-11. doi: https://doi.org/10.1038/s41698-018-0056-z DOI: https://doi.org/10.1038/s41698-018-0056-z
Wu P, Oren O, Gertz MA, et al. Proteasome inhibitorrelated cardiotoxicity: mechanisms, diagnosis, and management. Curr Oncol Rep. 2020;22(7):66. doi: https://doi.org/10.1007/s11912-020-00931-w DOI: https://doi.org/10.1007/s11912-020-00931-w
Arangalage D, Degrauwe N, Michielin O, et al. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors. Cancer Treat Rev. 2021;100:102282. doi: https://doi.org/10.1016/j.ctrv.2021.102282 DOI: https://doi.org/10.1016/j.ctrv.2021.102282
Bronte E, Bronte G, Novo G, et al. Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors. Pharmacol Ther. 2018;192:65-73. doi: https://doi.org/10.1016/j.pharmthera.2018.06.017 DOI: https://doi.org/10.1016/j.pharmthera.2018.06.017
Banfill K, Giuliani M, Aznar M, et al. Cardiac toxicity of thoracic radiotherapy: existing evidence and future directions. J Thorac Oncol. 2021;16(2):216-27. doi: https://doi.org/10.1016/j.jtho.2020.11.002 DOI: https://doi.org/10.1016/j.jtho.2020.11.002
Bittar CS, Fonseca SMR. Radioterapia e cardiotoxicidade. Rev Soc Cardiol Estado São Paulo. 2017;27(4):274-7. doi: https://doi.org/10.29381/0103-8559/20172704274-7 DOI: https://doi.org/10.29381/0103-8559/20172704274-7
Desai MY, Windecker S, Lancellotti P, et al. Prevention, diagnosis, and management of radiation-associated cardiac disease: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019;74(7):905-27. doi: https://doi.org/10.1016/j.jacc.2019.07.006 DOI: https://doi.org/10.1016/j.jacc.2019.07.006
Ezekowitz JA, O’Meara E, McDonald MA, et al. 2017 comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure. Can J Cardiol. 2017;33(11):1342-433. doi: https://doi.org/10.1016/j.cjca.2017.08.022 DOI: https://doi.org/10.1016/j.cjca.2017.08.022
Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474-502. doi: https://doi.org/10.1038/s41569-020-0348-1 DOI: https://doi.org/10.1038/s41569-020-0348-1
Wang H, Wei J, Zheng Q, et al. Radiation-induced heart disease: a review of classification, mechanism and prevention. Int J Biol Sci. 2019;15(10):2128-38. doi: https://doi.org/10.7150/ijbs.35460 DOI: https://doi.org/10.7150/ijbs.35460
Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of cancer-related treatment. Circ Res. 2016;118(6):1008-20. doi: https://doi.org/10.1161/circresaha.115.303633 DOI: https://doi.org/10.1161/CIRCRESAHA.115.303633
World Health Organization. Obesity: preventing and managing the global epidemic: report of a WHO consultation [Internet]. Geneva: WHO; 2000 [acesso 2025 jul 31]. Disponível em: https://iris.who.int/handle/10665/42330
Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica. Diretrizes brasileiras de obesidade 2016-ABESO [Internet]. 4. ed. São Paulo: ABESO; 2016. [Acesso 2025 jul 31] Disponível em: https://abeso.org.br/wp-content/uploads/2019/12/Diretrizes-DownloadDiretrizes-Brasileiras-de-Obesidade-2016.pdf
Humeniuk RE, Henry-Edwards S, Ali RL, et al. Self-help strategies for cutting down or stopping substance use (ASSIST) [Internet]. Geneva: World Health Organization; 2010. [acesso 2025 jul 31]. Disponível em: https://www.who.int/publicationsdetail-redirect/9789241599405
Bull FC, Al-Ansari SS, Biddle S, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020;54(24):1451-62. doi: https://doi.org/10.1136/bjsports-2020-102955 DOI: https://doi.org/10.1136/bjsports-2020-102955
Lopes CMM, Haas VJ, Dantas RAS, et al. Assessment scale of risk for surgical positioning injuries. Rev LatinoAm Enfermagem. 2016;24:e2704. doi: https://doi.org/10.1590/1518-8345.0644.2704 DOI: https://doi.org/10.1590/1518-8345.0644.2704
Carrozzino D, Patierno C, Guidi J, et al. Clinimetric criteria for patient-reported outcome measures. Psychother Psychosom. 2021;90(4):222-32. doi: https://doi.org/10.1159/000516599 DOI: https://doi.org/10.1159/000516599
Walter LC, Brand RJ, Counsell SR, et al. Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization. JAMA. 2001;285(23):2987-94. doi: https://doi.org/10.1001/jama.285.23.2987 DOI: https://doi.org/10.1001/jama.285.23.2987
Kent DM, Ruthazer R, Weimar C, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology. 2013;81(7):619-25. doi: https://doi.org/10.1212/wnl.0b013e3182a08d59 DOI: https://doi.org/10.1212/WNL.0b013e3182a08d59
Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-7. doi: https://doi.org/10.1182/blood-2007-10-116327 DOI: https://doi.org/10.1182/blood-2007-10-116327
Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet. 1997;350(9094):1795- 8. doi: https://doi.org/10.1016/S0140-6736(97)08140-3 DOI: https://doi.org/10.1016/S0140-6736(97)08140-3
Tobiano G, Marshall AP, Gardiner T, et al. Development and psychometric testing of the patient participation in bedside handover survey. Health Expect. 2022;25(5):2492-502. doi: https://doi.org/10.1111/hex.13569 DOI: https://doi.org/10.1111/hex.13569
Publicado
Como Citar
Edição
Seção
Licença
Os direitos morais e intelectuais dos artigos pertencem aos respectivos autores, que concedem à RBC o direito de publicação.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
